Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Potter

Showing results (801-810 of 836) with videos related to

Pageof 84
Sort By:
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
Journal of the American College of Radiology : JACR|November 2, 2024
ACR Appropriateness Criteria® Altered Mental Status, Coma, Delirium, and Psychosis: 2024 Update, Bruno P Soares, Robert Y Shih, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment|June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trialJavier Cortés, Hope S Rugo, Ahmad Awada, et al.
JAMA Neurology|June 16, 2020
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled TrialJerry R Mendell, Zarife Sahenk, Kelly Lehman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.
Anticancer Research|November 10, 2019
Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem CellsMargarita V Romanenko, Evgeniya V Dolgova, Ivan D Osipov, et al.
Vavilovskii Zhurnal Genetiki I Selektsii|March 4, 2021
[Characteristic of the active substance of the Saccharomyces cerevisiae preparation having radioprotective properties]G S Ritter, V P Nikolin, N A Popova, et al.
International Journal of Radiation Biology|July 14, 2020
Characterization of biological peculiarities of the radioprotective activity of double-stranded RNA isolated from <i>Saccharomyces сerevisiae</i>Genrikh S Ritter, Valeriy P Nikolin, Nelly A Popova, et al.
Pageof 84

Showing results (801-810 of 836) with videos related to

Sort By:
Pageof 84
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
Journal of the American College of Radiology : JACR|November 2, 2024
ACR Appropriateness Criteria® Altered Mental Status, Coma, Delirium, and Psychosis: 2024 Update, Bruno P Soares, Robert Y Shih, et al.
Blood Cancer Journal|May 27, 2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial, Ajay K Nooka, Praneetha Thulasi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment|June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trialJavier Cortés, Hope S Rugo, Ahmad Awada, et al.
JAMA Neurology|June 16, 2020
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled TrialJerry R Mendell, Zarife Sahenk, Kelly Lehman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.
Anticancer Research|November 10, 2019
Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem CellsMargarita V Romanenko, Evgeniya V Dolgova, Ivan D Osipov, et al.
Vavilovskii Zhurnal Genetiki I Selektsii|March 4, 2021
[Characteristic of the active substance of the Saccharomyces cerevisiae preparation having radioprotective properties]G S Ritter, V P Nikolin, N A Popova, et al.
International Journal of Radiation Biology|July 14, 2020
Characterization of biological peculiarities of the radioprotective activity of double-stranded RNA isolated from <i>Saccharomyces сerevisiae</i>Genrikh S Ritter, Valeriy P Nikolin, Nelly A Popova, et al.
Pageof 84